In Brief: NutraMax
This article was originally published in The Tan Sheet
Executive Summary
NutraMax: Forms special committee of its board to "explore strategic alternatives" for the company after MEDIQ announced in November that it may sell its 47% share of the private-labeler, NutraMax said June 19. The committee has hired Wasserstein Perella & Co. as financial advisors. Separately, NutraMax released expected earnings for the third quarter (ending June 30) of $.10-.11 per share, down from $.14 per share last year, due to "continued softness" in cough/cold sales from the mild winter. A backlog of customer cough/cold orders and new eye care product sales should help fuel a recovery in the fourth quarter, the firm said. Early sales of NutraMax's newest line, NutraMax Plus High Calorie Liquid Nutrition, are "very positive," the firm noted; three additional items are slated to be introduced in early fall...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning